DGAP-News: Apricus Biosciences Expands Commercial Oncology Offerings Through Agreement With Pediatrx for U.S. Co-Promotion of GRANISOL(R) (Granisetron) Oral Solution and AQUORAL(TM) Spray and Purchase of Non-U.S. Rights to GRANISOL(R)
Apricus Biosciences, Inc.
27.01.2012 14:00
—————————————————————————
SAN DIEGO and CALIFON, N.J., 2012-01-27 14:00 CET (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
(http://www.apricusbio.com) and PediatRx, Inc. (–PediatRx–) (OTCBB:PEDX)
(http://www.pediatrx.com) announced today the execution of a binding term sheet
for (1) the U.S. co-promotion of, and sale of non-U.S. rights to PediatRx–s
